Lancashire and South Cumbria
Formulary
Formulary
5 Infections
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
This chapter of the formulary is under development, please use local/national antimicrobial guidelines to support prescribing choices.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
The formulary development team can be contacted here: mlcsu.lscformulary@nhs.net
Prescribers must follow the relevant local and national guidance when treating an infection. Some anti-infectives require approval from the local Trust microbiology team for use, consult local guidance for further information.Not all anti-infectives listed in this chapter will be available in all localities; availability will be guided by local need and resistance patterns. |
05-03-03-02 Chronic hepatitis C
Hepatitis C therapy is based on genotype and cirrhosis status. Treatment options are dictated by the 'rate card' which is published by NHSE.
All cases in this region are discussed at the hepatitis C MDT for all local Trusts.
| Elbasvir with grazoprevir Zepatier® |
|
Formulary
|
Tablets elbasvir 50mg, grazoprevir 100mg |
 NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
|
| Glencaprevir with pibrentasvir |
|
Formulary
|
Tablets glecaprevir 100mg, pibrentasvir 40mg |
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
|
|
| Ledipasvir and Sofosbuvir Harvoni® |
|
Formulary
|
Tablets 45mg/200mg, 90mg/400mg |
|
MHRA: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
|
|
| Sofosbuvir Sovaldi® |
|
Formulary
|
Tablets 200mg, 400mg |
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
|
|
| Sofosbuvir and Velpatasvir Epclusa® |
|
Formulary
|
Tablets 200mg/50mg, 400mg/100mg |
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
|
| Sofosbuvir with Velpatasvir and Voxilaprevir Vosevi® |
|
Formulary
|
Tablets Sofosbuvir 400 mg, Velpatasvir 100mg, Voxilaprevir 100mg
|
|
NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
|
|
Links
- Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older) - Supply Disruption
Blackpool Teaching Hospitals: Antimicrobial Formulary- British Association for Sexual Health and HIV
- Central Lancashire/LSCFT/Morecambe Bay Primary Care: NICE Summary of antimicrobial prescribing guidance - managing common infections
- East Lancashire Primary Care: Antimicrobial guide primary care
- East Lancashire Secondary Care: Antimicrobial guide secondary care
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (App store)
- Lancashire Teaching Hospitals Secondary Care: Tap on the bugs app (Google)
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- LSCMMG: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
- MHRA Drug Safety Update Dec 18: Direct-acting antivirals for chronic hepatitis C: risk of hypoglycaemia in patients with diabetes
- MHRA Drug Safety Update Dec 18: Ritonavir-containing products: reports of interaction with levothyroxine leading to reduced thyroxine levels
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: COVID-19 antivirals: reporting to the UK COVID-19 Antivirals Pregnancy Registry
- MHRA: Direct-acting antiviral interferon-free regimens to treat chronic hepatitis C: risk of hepatitis B reactivation
- MHRA: Direct-acting antivirals to treat chronic hepatitis C: risk of interaction with vitamin K antagonists and changes in INR
- MHRA: Nirmatrelvir, ritonavir (Paxlovid▼): be alert to the risk of drug interactions with ritonavir
- MHRA: Sofosbuvir with daclatasvir; sofosbuvir and ledipasvir: risks of severe bradycardia and heart block when taken with amiodarone
- MHRA: Tocilizumab (RoActemra): rare risk of serious liver injury including cases requiring transplantation
- NHS England Interim Clinical Commissioning Policy: Remdesivir for patients hospitalised with COVID-19 (adults and children 12 years and older)
- NHSE: Clinical Commissioning Policy Statement: Treatment of chronic Hepatitis C in patients with cirrhosis
- NHSE: Urgent Clinical Commissioning Policy Statement: Retreatment of Chronic Hepatitis C Infection in Adults with Advanced or Decompensated Cirrhosis
- NICE CG165: Hepatitis B (chronic): diagnosis and management
- NICE ES27: COVID 19 rapid evidence summary: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19
- NICE NG120: Cough (acute): antimicrobial prescribing
- NICE NG125: Surgical site infections: prevention and treatment
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG191 COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG191: COVID-19 rapid guideline: managing COVID-19
- NICE NG240: Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management
- NICE NG51: Sepsis: recognition, diagnosis and early management
- NICE NG78: Cystic fibrosis: diagnosis and management
- NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
- NICE TA200:Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
- NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
- NICE TA330: Sofosbuvir for treating chronic hepatitis C
- NICE TA363 Ledipasvir–sofosbuvir for treating chronic hepatitis C
- NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
- NICE TA364 Daclatasvir for treating chronic hepatitis C
- NICE TA365 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
- NICE TA365 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
- NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
- NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
- NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
- NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
- NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
- NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
- NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
- NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
- NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878 Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA878: Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
- NICE TA900:Tixagevimab plus cilgavimab for preventing COVID-19
- NICE TA971: Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
- Publication of an interim clinical commissioning policy: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older).
- University Hospitals of Morecambe Bay: Antimicrobial guide secondary care
- West Lancashire Primary Care: Pan Mersey antimicrobial guide
- WHO: AWaRe classification of antibiotics for evaluation and monitoring of use, 2023